Major Clinical Impact of Platinum-Based Chemotherapy in a Patient with a Borderline Ovarian Cancer

Publisher： Karger

E-ISSN： 1662-6575|2|3|168-171

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.2, Iss.3, 2009-09, pp. : 168-171

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Improved Survival Trends in Platinum-Resistant Patients with Advanced Ovarian, Fallopian or Peritoneal Cancer Treated with First-Line Paclitaxel/Platinum Chemotherapy: The Impact of Novel Agents

By  

Oncology, Vol. 84, Iss. 3, 2012-12 ,pp. : 158-165

Karger

Access to resources Recommend Favorite

Role of DNA Repair Gene Polymorphisms in the Efficiency of Platinum-Based Adjuvant Chemotherapy for Non-Small Cell Lung Cancer

By Mathiaux Juliette   >  

Molecular Diagnosis & Therapy, Vol. 15, Iss. 3, 2011-06 ,pp. : 159-166

Adis International

Access to resources Recommend Favorite

A Retrospective Comparison of Docetaxel and Paclitaxel for Patients with Advanced or Recurrent Esophageal Cancer Who Previously Received Platinum-Based Chemotherapy

By  

Oncology, Vol. 81, Iss. 3-4, 2011-11 ,pp. : 237-242

Karger

Access to resources Recommend Favorite

Venous Thromboembolic Events in Germ Cell Cancer Patients Undergoing Platinum-Based Chemotherapy

By  

Oncology Research and Treatment, Vol. 36, Iss. 11, 2013-10 ,pp. : 663-668

Karger

Access to resources Recommend Favorite

How Does Inhibition of the Renin-Angiotensin System Affect the Prognosis of Advanced Gastric Cancer Patients Receiving Platinum-Based Chemotherapy?

By  

Oncology, Vol. 83, Iss. 6, 2012-10 ,pp. : 354-360

Karger

Access to resources Recommend Favorite